This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Transforming the lives of those suffering from vision loss

We are a biotechnology company with a mission to profoundly improve treatment options for patients with retinal vascular disease.
Our lead asset, EXN407 is poised to become the first topical therapy for diseases such as diabetic retinopathy and diabetic macular oedema and is set to enter Phase IIb clinical trials in 2024.